198 related articles for article (PubMed ID: 31187536)
1. What we should know about natural killer/T-cell lymphomas.
Xiong J; Zhao W
Hematol Oncol; 2019 Jun; 37 Suppl 1():75-81. PubMed ID: 31187536
[TBL] [Abstract][Full Text] [Related]
2. Advances in multiple omics of natural-killer/T cell lymphoma.
Xiong J; Zhao WL
J Hematol Oncol; 2018 Dec; 11(1):134. PubMed ID: 30514323
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and management of extranodal NK/T cell lymphoma nasal type.
Tse E; Kwong YL
Expert Rev Hematol; 2016 Sep; 9(9):861-71. PubMed ID: 27347812
[TBL] [Abstract][Full Text] [Related]
4. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations.
Lin GW; Xu C; Chen K; Huang HQ; Chen J; Song B; Chan JKC; Li W; Liu W; Shih LY; Chuang WY; Kim WS; Tan W; Peng RJ; Laurensia Y; Cheah DMZ; Huang D; Cheng CL; Su YJ; Tan SY; Ng SB; Tang TPL; Han K; Wang VY; Jia WH; Pei Z; Li YJ; Gao S; Shi Y; Hu Z; Zhang F; Zhang B; Zeng YX; Shen H; He L; Ong CK; Lim ST; Chanock S; Kwong YL; Lin D; Rothman N; Khor CC; Lan Q; Bei JX;
Lancet Oncol; 2020 Feb; 21(2):306-316. PubMed ID: 31879220
[TBL] [Abstract][Full Text] [Related]
5. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
[TBL] [Abstract][Full Text] [Related]
6. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study.
Li Z; Xia Y; Feng LN; Chen JR; Li HM; Cui J; Cai QQ; Sim KS; Nairismägi ML; Laurensia Y; Meah WY; Liu WS; Guo YM; Chen LZ; Feng QS; Pang CP; Chen LJ; Chew SH; Ebstein RP; Foo JN; Liu J; Ha J; Khoo LP; Chin ST; Zeng YX; Aung T; Chowbay B; Diong CP; Zhang F; Liu YH; Tang T; Tao M; Quek R; Mohamad F; Tan SY; Teh BT; Ng SB; Chng WJ; Ong CK; Okada Y; Raychaudhuri S; Lim ST; Tan W; Peng RJ; Khor CC; Bei JX
Lancet Oncol; 2016 Sep; 17(9):1240-7. PubMed ID: 27470079
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
8. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.
Peng RJ; Han BW; Cai QQ; Zuo XY; Xia T; Chen JR; Feng LN; Lim JQ; Chen SW; Zeng MS; Guo YM; Li B; Xia XJ; Xia Y; Laurensia Y; Chia BKH; Huang HQ; Young KH; Lim ST; Ong CK; Zeng YX; Bei JX
Leukemia; 2019 Jun; 33(6):1451-1462. PubMed ID: 30546078
[TBL] [Abstract][Full Text] [Related]
9. CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.
Yang J; Li P; Piao Y; Liu X; Wei L; Sang W; Zhang L; Wang L
Front Immunol; 2022; 13():829366. PubMed ID: 35371002
[TBL] [Abstract][Full Text] [Related]
10. The diagnosis and management of NK/T-cell lymphomas.
Tse E; Kwong YL
J Hematol Oncol; 2017 Apr; 10(1):85. PubMed ID: 28410601
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
Asano N; Kato S; Nakamura S
Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and treatment outcomes for patients with stage II extranodal nasal-type natural killer/T-cell lymphoma of the upper aerodigestive tract.
Fang H; Jin J; Wang WH; Wang SL; Zhou LQ; Li YX
Leuk Lymphoma; 2014 Aug; 55(8):1832-7. PubMed ID: 24144309
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of natural killer-cell malignancies.
Ishida F; Kwong YL
Expert Rev Hematol; 2010 Oct; 3(5):593-602. PubMed ID: 21083476
[TBL] [Abstract][Full Text] [Related]
14. Extranodal natural killer/T cell lymphoma: we should and we can do more.
Ying Z; Zhu J
Chin Clin Oncol; 2015 Mar; 4(1):12. PubMed ID: 25841719
[TBL] [Abstract][Full Text] [Related]
15. Updating targets for natural killer/T-cell lymphoma immunotherapy.
Xue W; Zhang M
Cancer Biol Med; 2021 Feb; 18(1):52-62. PubMed ID: 33628584
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities.
Kim WY; Nam SJ; Kim S; Kim TM; Heo DS; Kim CW; Jeon YK
Leuk Lymphoma; 2015 Jun; 56(6):1778-86. PubMed ID: 25288491
[TBL] [Abstract][Full Text] [Related]
17. Extranodal natural killer/T-cell lymphoma: advances in the management.
Jaccard A; Hermine O
Curr Opin Oncol; 2011 Sep; 23(5):429-35. PubMed ID: 21743325
[TBL] [Abstract][Full Text] [Related]
18. Circulating Epstein-Barr virus-encoded micro-RNAs as potential biomarkers for nasal natural killer/T-cell lymphoma.
Komabayashi Y; Kishibe K; Nagato T; Ueda S; Takahara M; Harabuchi Y
Hematol Oncol; 2017 Dec; 35(4):655-663. PubMed ID: 27709652
[TBL] [Abstract][Full Text] [Related]
19. HACE1, a potential tumor suppressor gene on 6q21, is not involved in extranodal natural killer/T-cell lymphoma pathophysiology.
Sako N; Dessirier V; Bagot M; Bensussan A; Schmitt C
Am J Pathol; 2014 Nov; 184(11):2899-907. PubMed ID: 25203537
[TBL] [Abstract][Full Text] [Related]
20. Management of NK/T-Cell Lymphoma, Nasal Type.
Allen PB; Lechowicz MJ
J Oncol Pract; 2019 Oct; 15(10):513-520. PubMed ID: 31600461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
